Synopsis

AbbVie Inc.	Individual Study Table Referring to Part of Dossier:	(For National Authority Use Only)
Name of Study Drug: Upadacitinib	Volume:	
Name of Active Ingredient: Upadacitinib	Page:	

Title of Study: A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)

Investigator: Dr. Atul Singhal.

Study Sites: 152 sites in 26 countries (Australia, Austria, Belgium, Canada, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Korea, Latvia, New Zealand, Poland, Portugal, Puerto Rico, Russian Federation, Slovakia, Spain, Sweden, Turkey, United Kingdom, United States)

Publications: None

Studied Period (Years): Phase of Development: 3

First Subject First Visit: 15 March 2016 Last Subject Last Visit: 27 June 2017 (Period 1)

Objectives:

The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo on a background of conventional synthetic DMARDs (csDMARDs) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA.

The study objective of Period 2 is to evaluate the long term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in subjects with RA who had completed Period 1.

This Clinical Study Report presents the results of Period 1 (i.e., through Week 24) only.

Methodology:

This was a Phase 3 multicenter study that included two periods. Period 1 was a 24-week, randomized, double-blind, parallel-group, placebo-controlled period designed to compare the safety and efficacy of upadacitinib 30 mg OD and 15 mg OD versus placebo for the treatment of signs and symptoms of subjects with moderately to severely active RA who were on a stable dose of csDMARDs and had an inadequate response to or intolerance to at least 1 bDMARD. Period 2 is a blinded long-term extension period to evaluate the long-term safety, tolerability, and efficacy of upadacitinib 30 mg QD and 15 mg QD in subjects with RA who had completed Period 1.

Methodology (Continued):

The study was designed to enroll approximately 450 subjects at approximately 300 study centers worldwide to meet scientific and regulatory objectives without enrolling an undue number of subjects in alignment with ethical considerations. Therefore, if the target number of subjects had been enrolled, there was a possibility that additional subjects in screening were not enrolled.

The study duration was to include a 35-day screening period; a 24-week randomized, double-blind, parallel-group, placebo controlled treatment period (Period 1); a 216-week blinded long-term extension period (Period 2); and a 30-day follow-up period (call or visit).

Subjects who met eligibility criteria were to be randomized in a 2:2:1:1 ratio to one of four treatment groups:

Group 1: upadacitinib 30 mg QD (N = 150) (Day 1 to Week 12) → upadacitinib 30 mg QD (Week 12 and thereafter)

Group 2: upadacitinib 15 mg QD (N = 150) (Day 1 to Week 12) → upadacitinib 15 mg QD (Week 12 and thereafter)

Group 3: Placebo (N = 75) (Day 1 to Week 12) \rightarrow upadacitinib 30 mg QD (Week 12 and thereafter)

Group 4: Placebo (N = 75) (Day 1 to Week 12) → upadacitinib 15 mg QD (Week 12 and thereafter) Subjects should have been on a stable dose of csDMARD(s) for ≥ 4 weeks prior to the first dose of study drug and should have remained on a stable dose until Week 24; the csDMARD dose was to be decreased only for safety reasons.

Number of Subjects (Planned and Analyzed):

Planned: 450 subjects (300 upadacitinib, 150 placebo); Analyzed: 498 subjects (329 upadacitinib, 169 placebo)

Diagnosis and Main Criteria for Inclusion:

Adult males and females enrolled in this study were at least 18 years old with a diagnosis of RA for ≥ 3 months and fulfilled the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for RA. Eligible study subjects must have had ≥ 6 swollen joints (based on 66 joint counts) and \geq 6 tender joints (based on 68 joint counts) at screening and baseline visits, and high sensitivity C-reactive protein ≥ 3 mg/L (central lab) at screening. Subjects have been treated with bDMARD therapy for RA in the past and failed at least 1 bDMARD therapy prior to first dose of study drug as defined by either not showing an adequate response to at least 1 bDMARD after a treatment of ≥ 3 months or having had to discontinue at least 1 bDMARD due to intolerability or toxicity, irrespective of treatment duration. Subjects were to have been on csDMARD therapy ≥ 3 months and on a stable dose of csDMARD therapy (restricted to methotrexate, chloroquine, hydroxychloroquine, sulfasalazine, or leflunomide) for ≥ 4 weeks prior to the first dose of study drug. Subjects were excluded if they had prior exposure to any janus kinase (JAK) inhibitor (including but not limited to tofacitinib, baricitinib, and filgotinib); had a history of inflammatory joint disease other than RA; and had laboratory values that met the following criteria within the screening period prior to the first dose of study drug: serum aspartate transaminase (AST) > 2 × upper limit of normal (ULN); serum alanine transaminase (ALT) $\geq 2 \times ULN$; estimated glomerular filtration rate by simplified 4-variable Modification of Diet in Renal Disease formula < 40 mL/min/1.73 m²; total white blood cell count $< 2,500/\mu$ L; absolute neutrophil count $< 1,500/\mu$ L; platelet count $< 100,000/\mu$ L; absolute lymphocyte count $< 800/\mu L$; and hemoglobin < 10 g/dL.



Test Product, Dose/Strength/Concentration, Mode of Administration and Lot Number:

Upadacitinib 15 mg extended release capsules for oral administration (bulk lot number: 15-005364, 16-001615)

Upadacitinib 30 mg extended release capsules for oral administration (bulk lot number: 15-005365, 15-005424, 15-005425, 16-001432)

Duration of Treatment: Period 1: 24 weeks; Period 2: up to 4 years

Reference Therapy, Dose/Strength/Concentration and Mode of Administration and Lot Number:

Matching placebo, capsules for oral administration (bulk lot number: 15-005363, 15-005362, 16-001360)

Criteria for Evaluation

For Period 1 (through Week 24), secondary and other efficacy variables defined in the statistical analysis plan were updated after finalization of Protocol Amendment 2 and are the variables presented, and include the following:

Efficacy:

The primary endpoint for US/Food and Drug Administration (FDA) regulatory purposes is the proportion of subjects achieving ACR20 response (ACR20) at Week 12. The primary endpoint for European Union (EU)/European Medicines Agency (EMA) regulatory purposes is the proportion of subjects achieving Low Disease Activity (LDA) based on disease activity score 28 (DAS28) (C-reactive protein [CRP]) ≤ 3.2 at Week 12.

Ranked key secondary endpoints (at Week 12) for US/FDA regulatory purposes were: 1) change from baseline in DAS28 (CRP); 2) change from baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI); 3) LDA as measured by DAS28 (CRP); 4) change from baseline in Short Form-36 (SF-36) physical component summary (PCS).

Ranked key secondary endpoints (at Week 12) for EU/EMA regulatory purposes were: 1) change from baseline in DAS28 (CRP); 2) ACR20 response rate; 3) change from baseline in HAQ-DI; 4) change from baseline in SF-36 PCS.

Other key secondary endpoints (at Week 12, if not specified) for both US/FDA and EU/EMA regulatory purposes were: 1) proportion of subjects achieving ACR 50 response (ACR50) rate; 2) proportion of subjects achieving ACR 70 response (ACR70) rate; 3) proportion of subjects achieving ACR20 response at Week 1.

Additional efficacy analyses included the following endpoints at all visits through Week 24: change from baseline in individual components of ACR response; ACR20/50/70 response rates; change from baseline in DAS28 (CRP) and DAS28 (erythrocyte sedimentation rate [ESR]); change from baseline in Clinical Disease Activity Index (CDAI) and Simple Disease Activity Index (SDAI); change from baseline in morning stiffness (severity and duration); proportion of subjects achieving LDA and proportion of subjects achieving clinical remission (CR) based on DAS28 (CRP), DAS28 (ESR), SDAI, and CDAI criteria; proportion of subjects achieving change from baseline in HAQ-DI ≤ −0.3 among those with baseline HAQ DI ≥ 0.3 and post-hoc, the proportion of subjects with change from baseline in $HAQ-DI \le -0.22$; ACR/EULAR Boolean remission; and the following endpoints at Weeks 4, 12 and 24: change from baseline in EuroQoL-5D-5L; change from baseline in Insomnia Severity Index (ISI); change from baseline in SF-36.

Pharmacokinetic: Blood samples for upadacitinib plasma concentrations were obtained throughout the study.



Criteria for Evaluation (Continued)

Safety:

Adverse events (AEs), physical examination, laboratory assessments, electrocardiogram (ECG), and vital signs data were assessed throughout the study.

Statistical Methods

Efficacy:

Primary Endpoint: Comparison of the primary endpoint was made between each upadacitinib dose group and the combined placebo groups using the Cochran-Mantel-Haenszel test adjusted for main stratification factors. For the primary analysis, Non-Responder Imputation (NRI) was used. The analysis was repeated using Observed Cases (OC). Supportive analysis was also conducted on the Per Protocol Analysis Set. The primary efficacy analyses were also performed in demographic subgroups including age, sex, weight, body mass index, race, and geographical region to assess the consistency of the treatment effect. Additional subgroup analyses based on baseline disease characteristics and stratification factors were also conducted.

Secondary Endpoints: For binary endpoints, frequencies and percentages were reported for each treatment group. Similar analyses as for the primary endpoint were conducted. For the major RA continuous endpoints DAS28 and HAQ-DI change from baseline at Week 12, statistical inference was conducted using analysis of covariance (ANCOVA) coupled with multiple imputation (MI) for missing data handling. Specifically, the ANCOVA model was to include treatment as the fixed factor, and the corresponding baseline value and the stratification factor prior bDMARD use (Stratum 1: failed 1 or 2 biologics with the same mechanism of action; Stratum 2: failed ≥ 3 prior bDMARDs with the same mechanism of action and/or multiple mechanisms of action) as the covariates. For other continuous endpoints, statistical inference was conducted using the Mixed Effect Model Repeat Measurement (MMRM) model with fixed effects of treatment, visit and treatment by-visit interaction, prior bDMARD use (stratum 1/stratum 2), and baseline value as covariate. For both the MI and MMRM analyses, the least square (LS) mean and 95% confidence interval (CI) were to be reported for each randomized treatment group; the LS mean treatment difference and associated 95% CI and p-value were to be reported comparing each upadacitinib dose group with the combined placebo group. Both nominal p value and adjusted p-value through the graphical multiplicity procedure were to be provided. Additional Efficacy Variables: For binary endpoints, point estimate and 95% CI using normal approximation were to be provided for the response rate for each randomized treatment group. Point estimate, 95% CI, and p-value were to be provided for the treatment comparison between each upadacitinib dose group and the combined placebo group using the Cochran Mantel Haenszel test, adjusting for stratification factor of prior bDMARD use. Only nominal p-value was to be provided, and the 95% CI was to be based on normal approximation. NRI was to be used as primary analysis. For continuous endpoints, the LS mean and 95% CI were to be reported for each randomized treatment group. The LS mean treatment difference and associated 95% CI and p-values between each upadacitinib dose group and the combined placebo group was to be provided using MMRM model with fixed effects of treatment, visit and treatment by-visit interaction, prior bDMARD use, and baseline value as covariate. Only nominal p-value was to be provided.

Pharmacokinetic:

Individual upadacitinib plasma concentrations at each study visit were tabulated and summarized with appropriate statistical methods.



Statistical Methods (Continued)

Safety:

Safety analyses were based on treatments actually received. Safety was assessed by AEs, physical examination, laboratory assessments, ECG, and vital signs. Frequency tables and lists of subjects with treatment-emergent AEs (TEAEs) by preferred term as in the Medical Dictionary for Regulatory Activities (MedDRA) dictionary, by system organ class, by severity, and by relationship to the study drug as assessed by the investigator were provided.

The changes from baseline in vital signs and laboratory values were examined. Shift of laboratory values from baseline to defined time points was tabulated. Missing safety data were not imputed.

Summary/Conclusions

Efficacy Results:

In this blinded, placebo-controlled period, upadacitinib at doses of 15 mg and 30 mg QD with a background of csDMARD therapy for 12 weeks was effective in the treatment of subjects with moderately to severely active RA who have had an inadequate response or intolerance to at least 1 bDMARD. The study met its primary endpoints at Week 12, with a highly statistically significantly greater percentage of subjects achieving an ACR20 response in both the upadacitinib 15 mg and 30 mg groups compared with the placebo group. Similarly, a highly statistically significantly greater proportion of subjects in both the upadacitinib 15 mg and 30 mg groups achieved LDA based on DAS28 $(CRP) \le 3.2$ compared with the placebo group. The study also met all ranked and other key secondary endpoints with high statistical significance in the upadacitinib dose groups compared with the placebo group, with the exception of ACR70 in the upadacitinib 15 mg group at Week 12. Notably, a similar proportion of subjects originally assigned to placebo who switched to upadacitinib 15 mg at Week 12 achieved ACR70 at Week 24 compared to the ACR 70 response rate at Week 12 among those initially randomized to upadacitinib 30 mg. Continued improvement beyond Week 12 was also demonstrated with the majority (> 50%) of subjects in both upadacitinib dose groups achieving LDA based on DAS28 (CRP) at Week 24.

Rapid onset of efficacy was noted with both upadacitinib doses achieving statistical significance for several efficacy variables as early as Week 1, and improvement was sustained through Week 12. For subjects who were on upadacitinib 15 or 30 mg from baseline through Week 24, efficacy response was either maintained or further improved. Efficacy results in this study were consistent with those observed in the Phase 2 study (Study M13-550), in a similar population.

Pharmacokinetic Results:

Within the 24-hour dosing interval, the mean plasma concentrations for upadacitinib ranged from 6.48 ng/mL to 37.3 ng/mL for subjects who received upadacitinib 15 mg OD (whether from the start of the study or switching from placebo) and from 12.1 ng/mL to 66.4 ng/mL for subjects who received upadacitinib 30 mg QD (whether from the start of the study or switching from placebo). The observed upadacitinib concentrations were consistent with the predicted concentrations based on prior pharmacokinetic evaluations of upadacitinib.

Safety Results:

In this blinded, placebo-controlled study treatment with upadacitinib for 12 weeks and through 24 weeks of continued blinded treatment, upadacitinib at doses of 15 mg and 30 mg was generally well tolerated as assessed by the frequency of TEAEs, including serious adverse events (SAEs), adverse events of special interest (AESIs), clinical laboratory values, and vital signs values.



Summary/Conclusions (Continued)

Safety Results (Continued):

Through Week 24, 2 deaths were reported in the study: 1 subject in the upadacitinib 15 mg group with a cause of death reported as cardiac arrest (adjudicated to undetermined/unknown) and 1 subject in the upadacitinib 30 mg group with a cause of death of pulmonary embolism and cardiac failure (adjudicated to non-cardiovascular death). Both deaths were assessed as having no reasonable possibility of being related to study drug.

Through Week 12 the most frequently reported TEAEs (\geq 5% of subjects in any treatment group) were upper respiratory tract infection, nasopharyngitis, urinary tract infection, and rheumatoid arthritis. The most frequently reported TEAEs through Week 24 were the same as through Week 12, with the addition of headache.

Through Week 12, the percentage of subjects with TEAEs leading to discontinuation of study drug was higher in the upadacitinib 30 mg group (9.1%) than in the upadacitinib 15 mg (2.4%) and placebo (5.3%) groups. Through Week 24, the rate of TEAEs leading to discontinuation of study drug continued to be higher in the upadacitinib 30 mg (31.5 events [E]/patient-years [PY]) compared with the upadacitinib 15 mg group (19.2 E/PY).

Through Week 12, the percentage of subjects with SAEs was higher in the upadacitinib 30 mg group (7.3%) compared with the upadacitinib 15 mg group (4.9%) and there were no SAEs reported in the placebo group. Similarly, through Week 24, the rate of SAEs was higher in the upadacitinib 30 mg group (33.8 E/100 PY) compared with the upadacitinib 15 mg group (28.2 E/100 PY).

Through Week 12, the frequency of AESIs in the upadacitinib groups was generally similar compared with the placebo group, with the exception of serious infection, neutropenia, and blood creatine phosphokinase (CPK) elevation, which were reported by a higher percentage of subjects in the upadacitinib groups. Through Week 12, no subject in any treatment group had treatment emergent nonmelanoma skin cancer (NMSC), lymphoma, gastrointestinal (GI) perforation, renal dysfunction, or active/latent tuberculosis (TB). Through Week 12, herpes zoster infections were reported in 6 subjects. All events of herpes zoster were considered by the investigator to have a reasonable possibility of being related to study drug with the exception of the event of herpes zoster in the placebo group. Two events of herpes zoster in the upadacitinib 30 mg group were serious. Oral candidiasis was the only treatment emergent opportunistic infection reported through Week 12 (1 subject in the upadacitinib 15 mg group and 2 subjects in the upadacitinib 30 mg group). Through Week 12, there were 3 cases of malignancies: 1 subject in the upadacitinib15 mg group had malignant melanoma in situ (Day 82), and 2 subjects in the upadacitinib 30 mg group had a treatment-emergent malignancy of prostate cancer (Day 8 and Day 84). The percentage of drug-related hepatic disorders was similar across the treatment groups. Through Week 12, there was a single major adverse cardiovascular event (MACE) of non-fatal stroke in a subject who received upadacitinib 15 mg, which was reported by the investigator as having no reasonable possibility of being related to study drug. This subject had cardiovascular risk factors at study entry. AESIs also included abnormal labs reported by investigators as TEAEs. Through Week 12, there were no TEAEs of anemia. Equal numbers of subjects had TEAEs of lymphopenia across all treatment groups: 2 subjects each for upadacitinib 15 mg, 30 mg, and placebo groups. Through Week 12, TEAEs of neutropenia and blood CPK elevation were only reported in the upadacitinib groups. No subject had rhabdomyolysis or discontinued study drug due to a TEAE of blood CPK elevation.



Summary/Conclusions (Continued)

Safety Results (Continued):

Safety data through Week 24 analyzed as events per 100 PY showed that the rates of serious infection, hepatic disorder, neutropenia, herpes zoster, anemia, and blood CPK elevation appeared to be dosedependent. The rates of any malignancy other than NMSC, rates of GI perforation, and rates of lymphopenia were similar for subjects in the upadacitinib 15 mg and 30 mg groups. Through Week 24, no subject in any treatment group had treatment emergent NMSC, lymphoma, or active/latent TB. Through Week 24, the rate of serious infections was higher in the upadacitinib 30 mg group than in the 15 mg group (8.2 E/100 PY vs 4.5 E/100 PY). Through Week 24, serious herpes zoster was reported in 2 subjects in the upadacitinib 30 mg group; both had ophthalmic involvement and one case involved multiple dermatomes. There was 1 additional event of opportunistic infection from Week 12 through Week 24 which was an event of mucocutaneous candidiasis (upadacitinib 30 mg). Between Week 12 and Week 24 one additional treatment emergent malignancy of bladder cancer was reported in a subject in the upadacitinib 15 mg group. There was a higher rate of non-serious hepatic disorder reported in the upadacitinib 30 mg group (21.0 E/100 PY) compared with the upadacitinib 15 mg group (7.9 E/100 PY). Through Week 24, there was 1 serious event of GI perforation in the upadacitinib 30 mg group which was life-threatening in severity. Through Week 24, 3 events of renal dysfunction were reported in the upadacitinib groups only. There were 3 additional adjudicated cardiovascular events from Week 12 to Week 24: 2 subjects in the upadacitinib 15 mg group (coronary artery disease [adjudicated to cardiovascular procedure] and cardiac arrest [adjudicated to undetermined/unknown] which resulted in death) and 1 subject in the upadacitinib 30 mg group (non-fatal myocardial infarction). Subjects with adjudicated cardiovascular events had cardiovascular risk factors at study entry.

Two subjects had events coded to the preferred term pulmonary embolism through Week 12 (1 in the 15 mg and 1 in the 30 mg dose group); no pulmonary embolism or deep vein thrombosis events were observed during treatment with placebo. Between Week 12 and Week 24, 4 more events coded to the preferred term pulmonary embolism were reported in subjects during upadacitinib treatment. These 6 events were retrospectively adjudicated in a blinded fashion after database lock for Period 1. The Cardiovascular Adjudication Committee (CAC) determined that 4 of these events were confirmed pulmonary embolism events: 1 event was determined by the CAC to have insufficient evidence to be a confirmed pulmonary embolism and 1 event was considered by the CAC to be not assessable with the available information and was adjudicated to non-cardiovascular death.

For AESIs of abnormal labs, the rate of events of anemia was higher in the upadacitinib 30 mg group (8.2 E/100 PY) compared with the upadacitinib 15 mg group (4.5 E/100 PY). Through Week 24, neutropenia was reported in the upadacitinib groups only, while the rate of lymphopenia was higher in the placebo group. Through Week 24, blood CPK elevation was reported in the upadacitinib groups only; no subject had rhabdomyolysis or discontinued study drug due to a TEAE of blood CPK elevation. Among subjects with TEAEs of lymphopenia or neutropenia, no subject discontinued study drug due to these TEAEs.



Summary/Conclusions (Continued)

Safety Results (Continued):

Through Week 12 and through Week 24, group mean values for key hematology variables (hemoglobin, hematocrit, lymphocytes, neutrophils, platelets, and IgM and IgG) were generally within the normal reference range at baseline and at all visits for the upadacitinib and placebo groups. Through Week 12, 4 subjects (1 each in 15 mg and placebo and 2 in 30 mg) had Grade 3 or 4 hemoglobin values that were decreased at ≥ 2 time points during the treatment period. Through Week 24, the number of subjects with Grade 3 decreases in neutrophil values were comparable in the upadacitinib 30 mg group (5 subjects, 2.1%, each) and the upadacitinib 15 mg group (3 subjects, 1.3%). Two subjects in the upadacitinib 15 mg group each had a decrease in neutrophil value that was Grade 4. Of these 10 subjects with Grade 3 or Grade 4 decreases in neutrophil values, 3 subjects in the upadacitinib 15 mg group had Grade 3 or 4 values at ≥ 2 time points during the treatment period.

Grade 3 increases in blood CPK values were reported in 3 subjects who received upadacitinib (1 in 15 mg and 2 in 30 mg). One subject in the upadacitinib 30 mg group had a Grade 4 increase in blood CPK. None had rhabdomyolysis. Few subjects had increases in ALT or AST values that were Grade 3 or Grade 4. No subject had an increase in serum creatinine value that was Grade 3 or Grade 4. No Grade 3 or 4 increases in serum creatinine were observed in any subjects who received upadacitinib. Greater increases in both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were observed with upadacitinib treatment compared with placebo.

Mean changes from baseline to Week 12 and through Week 24 for vital signs in all the upadacitinib groups were not considered to be clinically meaningful compared with placebo.

Conclusions:

Through Week 12 of Study M13-542, superiority was consistently demonstrated for upadacitinib 15 mg and 30 mg QD versus placebo for both clinical responses and patient-reported health outcome results in subjects with moderately to severely active RA who were on a stable dose of csDMARDs and have had an inadequate response or intolerance to at least 1 bDMARD. The benefit: risk profile of both doses of upadacitinib is assessed as favorable based on review of the efficacy and safety results.


Date of Report: 23Jul2018




Protocol Changes

At the time of the data cutoff for this Period 1 clinical study report, the original protocol (21 January 2016, 3 subjects enrolled) had 2 global amendments and 9 country-specific amendments. The majority of changes to the protocol were responses to regulatory feedback, clarifications and editorial changes. The amendments, number of subjects enrolled under each amendment, country-specific protocol changes, substantial protocol changes were as follows:

- Amendment 1 (29 February 2016, 427 subjects enrolled) included revisions to the inclusion criteria to clarify requirements of pregnancy testing and women of childbearing potential, to avoid ambiguity regarding RA classification criteria. Text was added to clarify contraception requirements for background RA medication and follicle stimulating hormone (FSH) testing for females, including adding countries with local requirements. Criteria were added for adjusting or adding background medication at Week 24 if subjects did not achieve LDA as defined by CDAI. Text was added to clarify tuberculosis (TB) assessment and testing, ECG procedures, and the CDAI calculation. Preliminary results from ongoing relative bioavailability and Phase 2 studies were added.
- Amendment 1.01 (Sweden only) (06 May 2016, 3 subjects enrolled) was updated to include information of potential risks and benefits from the Investigator Brochure and discontinuation criteria language to Period 2. Discontinuation criteria for subjects were revised to reflect LDA as stopping criterion at Week 48/52 for subjects who have been exposed to bDMARDs from < 2 distinct mechanisms of action (MOA). Clarified stopping criteria for the remainder of the subjects.
- Amendment 1.02 (France only) (09 May 2016, 5 subjects enrolled) updated the study duration for Period 2 from 216 weeks to 24. Text was clarified to state that subjects who develop any malignancy were to be discontinued from study drug. Exclusion criteria were updated to remove "except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix" to clarify target group. Serum pregnancy test was added to be done at Baseline visit. Removed text regarding annual TB




- testing and chest x-ray every 48 weeks. Deleted "every 48 weeks thereafter" for 12-Lead electrocardiogram (ECG).
- Amendment 1.03 (Denmark only) (16 June 2016, 0 subjects) updated study duration for Period 2 from 216 weeks to 96 weeks and clarified Week 120 as the final visit.
- Amendment 2 (10 October 2016, 60 subjects) was updated to clarify that there were different primary efficacy variables for different regulatory purposes. Revisions updated inclusion criteria text to accommodate geographic differences in MTX dosing, to remove failure of csDMARDs, and to be more in line with expected pharmacodynamics of these drugs and standard practice. Revisions were made to the exclusion criteria to clarify the highest risk for gastrointestinal (GI) perforation with interleukin (IL)-6 and JAK inhibitors is for the lower GI tract, to update laboratory values within the screening period to reflect normal laboratory value reference ranges in the elderly population, and to reflect lack of QTc prolongation with upadacitinib. Guidance text was provided for washout of csDMARDs and permitted background RA therapy. Traditional Chinese medicine was added as prohibited. ECG and in vivo biomarkers at the final/premature discontinuation visit were added to the schedule of activities.
- Amendment 2.01 (Sweden only) (26 October 2016, 1 subject enrolled) was updated clarify that there were different primary efficacy variables for different regulatory purposes. Revisions updated inclusion criteria text to accommodate geographic differences in MTX dosing, to remove failure of csDMARDs, and to be more in line with expected pharmacodynamics of these drugs and standard practice. Revisions were made to the exclusion criteria to clarify the highest risk for GI perforation with IL-6 and JAK inhibitors is for the lower GI tract, to update laboratory values within the screening period to reflect normal laboratory value reference ranges in the elderly population, and to reflect lack of QTc prolongation with upadacitinib. Guidance text was provided for washout of csDMARDs and permitted background RA therapy. Oral traditional Chinese medicine was added as prohibited medication. Updated text regarding the selection of doses in the study with more recent data from the Phase 1 study. Added creatine phosphokinase (CPK) eCRF to



be completed as appropriate. Added that ECG and in vivo biomarkers will be done at final/premature discontinuation visit.


- Amendment 2.02 (France only) (26 October 2016, 0 subjects enrolled) was updated clarify that there were different primary efficacy variables for different regulatory purposes. Revisions updated inclusion criteria text to accommodate geographic differences in MTX dosing, to remove failure of csDMARDs, and to be more in line with expected pharmacodynamics of these drugs and standard practice. Revisions were made to the exclusion criteria to clarify the highest risk for GI perforation with IL-6 and JAK inhibitors is for the lower GI tract, update laboratory values within the screening period to reflect normal laboratory value reference ranges in the elderly population, and to reflect lack of QTc prolongation with upadacitinib. Guidance text was provided for washout of csDMARDs and permitted background RA therapy. Oral traditional Chinese medicine was prohibited. Updated text regarding the selection of doses in the study with more recent data from the Phase 1 study. A CPK eCRF was added to be completed, as appropriate. ECG and in vivo biomarkers at the final/premature discontinuation visit were added to the schedule of activities.
- Amendment 2.03 (Denmark only) (26 October 2016, 0 subjects enrolled) was updated clarify that there were different primary efficacy variables for different regulatory purposes. Revisions updated inclusion criteria text to accommodate geographic differences in MTX dosing, to remove failure of csDMARDs, and to be more in line with expected PD of these drugs and standard practice. Revisions were made to the exclusion criteria to clarify the highest risk for GI perforation with IL-6 and JAK inhibitors is for the lower GI tract, update laboratory values within the screening period to reflect normal laboratory value reference ranges in the elderly population, and to reflect lack of QTc prolongation with upadacitinib. Guidance text was provided for washout of csDMARDs and permitted background RA therapy. Oral traditional Chinese medicine was prohibited. Updated text regarding the selection of doses in the study with more recent data from the Phase 1 study. CPK eCRF was added to be completed as appropriate. ECG and in vivo biomarkers at the final/premature discontinuation visit were added to the schedule of activities.



- Amendment 2.02.01 (France only) (09 December 2016, 0 subjects) added text to provide clarification of hepatic and renal AE collection.
- Amendment 2.02.02 (France only) (18 April 2017, 0 subjects enrolled) extended the observation period from 48 weeks to 144 weeks in order to allow continued treatment with study drug.
- Amendment 2.02.03 (France only) (21 June 2017, 0 subjects) extended the observation period from 48 weeks to 120 weeks in order to allow continued treatment with study drug.

The original protocol and protocol amendments are provided in Appendix 16.1_1.

The protocol changes described in the amendments did not affect the interpretation of the results of the study.




List of Investigators and Sites


Investigator Name	Site Name/Post Office Address
Abril, Annette	Arthritis Associates of Kingsport
	Three Sheridan Square
	KINGSPORT, TN 37660
	United States
Aelion, Jacob	West Tennessee Research Institute
	Suite 400
	369 North Parkway
	JACKSON, TN 38305
	United States
Akinci Tan, Aysen	Hacepttepe University Faculty of Medicine
	Physical Therapy and Rehabilitation Sihhiye
	ANKARA, 06100
	Turkey
Alissa, Hassan	Arthritis Clinic of Central Texas
	Bldg. 2, Suite 2203
	1340 Wonder World Dr.
	SAN MARCOS, TX 78666
	United States
Alper, Jeffrey	Jeffrey Alper MD Research
	689 Ninth Street North
	NAPLES, FL 34102
	United States
Amin, Mona	Arizona Research Center, Inc.
	Suite 114
	2525 W. Greenway Road
	PHOENIX, AZ 85023
	United States
Andersone, Daina	Pauls Stradins Clinical University Hospital
	Center of Rheumatology
	Pilsonu Str. 13
	RIGA, 1002
	Latvia




Investigator Name	Site Name/Post Office Address
Antolini, Christopher	Denver Arthritis Clinic, PC
	Suite 100
	200 Spruce Street
	DENVER, CO 80230
	United States
Baraf, Herbert	The Center for Rheumatology & Bone Research
	Suite 306
	2730 University Boulevard West
	WHEATON, MD 20902
	United States
Baraliakos, Xenofon	Rheumazentrum Ruhrgebiet
	St. Elisabeth Gruppe GmbH
	Katholische Kliniken Rhein-Ruhr
	Claudiusster. 45
	HERNE, 44649
	Germany
Bennett, Ralph	Arizona Arthritis & Rheumatology Research, PLLC
	Suite 170
	4550 East Bell Road
	PHOENIX, AZ 85032
	United States
Bhagat, Shweta	West Suffolk NHS Foundation Trust
	Hardwick Lane,
	BURY ST EDMUNDS, SUFFOLK, IP33 2QZ
	United Kingdom
Birbara, Charles	Clinical Pharmacology Study Group
	25 Oak Avenue
	WORCESTER, MA 01605
	United States
Blanco Alonso, Ricardo	Hospital Universitario Marques de Valdecilla
	Reumatologia
	2ª planta. Pasillo 1. Valdecilla Sur. Edificio consultas
	Av. de Valdecilla s/n
	SANTANDER, CANTABRIA, 39008
	Spain



Investigator Name	Site Name/Post Office Address
Budd III, John	Clayton Medical Associates, PC
	Suite 110
	6400 Clayton Road
	ST. LOUIS, MO 63117
	United States
Burmester, Gerd-Ruediger	Charite Campus Mitte
	Universitatsmedizin Berl Medizinische Klinik mit
	Schwerpunkt Rheumatologie und klinische Immunologie
	Neue Therapien - Sekretariat
	BERLIN, 10117
	Germany
Bushan, Naga	Arthritis & Osteoporosis Associates, LLP
	5220 80th Street
	LUBBOCK, TX 79424
	United States
Caciolo, Barbara	St. Louis Center for Clinical Research
	Suite 101
	10012 Kennerly Road
	ST. LOUIS, MO 63128
	United States
Cantagrel, Alain	Hopital Purpan, Hospital Pierre-Paul Riquet
5	Service de Rhumatologie - Pole Institut Locomoteur
	Place du Docteur Baylac, Cedex 9
	TOULOUSE, TSA 40031 - 31059
	France
Carter, John	University of South Florida
,	Health Morsani Center for Advanced Healthcare
	MDC 81
	12901 Bruce B. Downs Boulevard
	TAMPA, FL 33612
	United States
Chapurlat, Roland	Hopital Edouard Herriot
Chapuriat, Roland	SERVICE DE RHUMATOLOGIE ET PATHOLOGIE
	OSSEUSE
	5 PLACE D'ARSONVAL
	LYON CEDEX 03, 69437
	France



Investigator Name	Site Name/Post Office Address
Charles-Schoeman, Christina	UCLA
	#32-59
	1000 Veteran Avenue
	LOS ANGELES, CA 90095
	United States
Ching, Daniel	Timaru Medical Specialists Limited
	28 Carlisle Place
	TIMARU, SOUTH CANTERBURY, 7910
	New Zealand
Chiu, Yee Ho	Arrowe Park Hospital
	Arrowe Park Road
	UPTON, WIRRAL, CH49 5PE
	United Kingdom
Codding, Christine	Health Research of Oklahoma
	Suite 409
	1211 North Shartel Avenue
	OKLAHOMA CITY, OK 73103
	United States
Cortes-Maisonet, Gregorio	GCM Medical Group, PSC
	1826 Avenue Fernandez Juncos
	SAN JUAN, 00909
	Puerto Rico
Cush, John	Baylor Research Institute/Arthritis Care and Diagnostic Center
	Ste 550
	9900 N. Central Expy
	DALLAS, TX 75231
	United States
Dhar, Rajat	Atlantic Coast Research
	442 D Commons Way
	TOMS RIVER, NJ 08755
	United States
Diri, Erdal	Trinity Health Medical Arts Clinic
	400 Burdick Expressway East
	MINOT, ND 58701
	United States



Investigator Name	Site Name/Post Office Address
Dokoupilova, Eva	Medical Plus, s.r.o.
	Obchodni 1507
	UHERSKE HRADISTE, 686 01
	Czech Republic
Dore, Robin	Robin K. Dore MD, Inc
	Suite 201
	12791 Newport Avenue
	TUSTIN, CA 92780
	United States
Drescher, Edit	Vital Medical Center Orvosi es Fogaszati Kozpont
	Jozsef Attila utca 17.
	VESZPREM, 8200
	Hungary
Dudek, Anna	Centrum Medyczne AMED
	ul. Gen. J. Zajaczka 9B/U1
	WARSAW, 01-518
	Poland
Durez, Patrick	Cliniques Universitaires Saint-Luc
	Avenue Hippocrate 10
	BRUSSELS, 1200
	Belgium
Everding, Andrea	HRF II-Hamburger Rheumaforschungs-zentrum II
	MVZ fur Rheumatologie u. Autoimmunmedizin Hamburg
	GmbH
	Monckebergstr. 27
	HAMBURG, 20095
	Germany
Fenton, Ira	Deerbrook Medical Associates
	Suite 116
	565 Lakeview Parkway
	VERNON HILLS, IL 60061
	United States



Investigator Name	Site Name/Post Office Address
Fernandez, Antonio	Hospital Regional Universitario de Malaga
	Unidad de Investigacion, Servicio de Reumatologia
	Pabellon Hospital Civil, 2a planta
	Plaza del Hospital Civil s/n
	MALAGA, 29009
	Spain
Fernandez, Benidecto	Lakes Research, LLC
	Suite 300
	5801 N.W. 151 Street
	MIAMI LAKES, FL 33104
	United States
Fischer, Peter	Mansfield Health Center
	200 Copeland Drive
	MANSFIELD, MA 02048
	United States
Fitzgerald, Oliver	St Vincent's University Hospital
	Elm Park
	DUBLIN, D04 T6F4
	Ireland
Fleischmann, Roy	Metroplex Clinical Research Center
	Suite 810
	8144 Walnut Hill Lane
	DALLAS, TX 75231
	United States
Flint, Kathleen	Columbia Arthritis Center
	1711 Saint Julian Place
	COLUMBIA, SC 29204
	United States
Freire Gonzalez, Mercedes	Complexo Hospitalario Universitario A Coruna
	Servicio de Reumatologia
	6 planta
	Ctra. Xubias de Arriba, 84
	A CORUNA, 15006
	Spain




Investigator Name	Site Name/Post Office Address	
Gaal, Janos	Kenezy Gyula Korhaz es Rendelointezet Reumatologiai Osztaly Bartok Bela u. 2-26	
	DEBRECEN, 4031 Hungary	
Garcia Meijide, Juan	Clinica Gaias, Santiago Servicio de Reumatología Rua do Pintor Xaime Quesada, 2-4, A Coruna SANTIAGO DE COMPOSTELA, 15702 Spain	
Genovese, Mark	Stanford University School of Medicine 1000 Welch RD #203 PALO ALTO, CA 94304 United States	
Gladstein, Geoffrey	New England Research Associates, LLC Suite M2-100 5520 Park Avenue TRUMBULL, CT 06611 United States	
Gonzalez-Paoli, Julio	St. Anthony Comprehensive Research Institute Suite 207 1201 5th Avenue ST. PETERSBURG, FL 33705 United States	
Goodman, Leslie	Diagnostic Group Integrated Health Systems, PLLC 3282 College Street BEAUMONT, TX 77701 United States	
Goodman, Robert	Vanguard Medical Research, LLC 740 Jordan Street SHREVEPORT, LA 71101 United States	
Greenwald, Maria	Desert Medical Advances Suite A-6 72855 Fred Waring Drive PALM DESERT, CA 92260 United States	



Investigator Name	Site Name/Post Office Address
Grisanti, Michael	Buffalo Rheumatology and Medicine PLLC
	Suite 100
	3055 Southwestern Boulevard
	ORCHARD PARK, NY 14127
	United States
Gupta, Ramesh	Dr. Ramesh Gupta
	Suite 409
	6005 Park Avenue
	MEMPHIS, TN 38119
	United States
Hall, Stephen	Emeritus Research
	291 Wattletree Road
	MALVERN EAST, VIC 3145
	Australia
Herron Box, Emily	DJL Clinical Research, PLLC
	Suite 110,
	10502 Park Road,
	CHARLOTTE, NC 28210
	United States
Ho, Gerald	Arthritis & Osteoporosis Medical Center
	Suite 25
	5451 La Palma Avenue
	LA PALMA, CA 90623
	United States
Horowitz, Diane	Northwell Health Division of Rheumatology
	Suite 302
	865 Northern Boulevard
	GREAT NECK, NY 11021
	United States
Huff, John	Arthritis & Osteoporosis Center of South Texas
	Suite 105
	14615 San Pedro Avenue
	SAN ANTONIO, TX 78232
	United States



Investigator Name	Site Name/Post Office Address	
Hultgard Ekwall, Anna-Karin	Sahlgrenska University Hospital	
	Clinical Trial Unit, Rheumatology	
	Grona straket 14	
	GOTHENBURG, 413 45	
	Sweden	
Irfan, Muhammad	DM Clinical Research	
	Suite 190	
	13406 Medical Complex Drive	
	TOMBALL, TX 77375	
	United States	
Jain, Manish	Great Lakes Clinical Trials	
	5149 North Ashland Avenue	
	CHICAGO, IL 60640	
	United States	
Jarvinen, Pentti	Kiljava Medical Research	
	Donnerinkatu 5	
	HYVINKAA, 05800	
	Finland	
Jimenez, Richard	Western Washington Arthritis Clinic	
	Suite 211	
	1909 214th St SE	
	BOTHELL, WA 98021	
	United States	
Jover Jover, Juan	Hospital Universitario Clinico San Carlos	
	Servicio de Reumatologia	
	4a planta	
	C/ Prof Martin Lagos, s/n	
	MADRID, 28040	
	Spain	
June, Joshua	June DO, PC	
	Suite C	
	3394 East Jolly Road	
	LANSING, MI 48910	
	United States	




R&1	D/1	7/0	0634
$1 \times \infty$	レ / 1	. // \	τ

Investigator Name	Site Name/Post Office Address
Kaine, Jeffrey	Lovelace Scientific Resources, Inc.
	Suite C
	411 Commercial Court
	VENICE, FL 34292
	United States
Kapil, Sanjiv	Omega Research Consultants, LLC
	609 North Charles Richard Beall Boulevard
	DEBARY, FL 32713
	United States
Karplus, Theresa	The Vancouver Clinic Inc. PS
	700 Northeast 87th Avenue
	VANCOUVER, WA 98664
	United States
Kauppi, Markku	Paijat-Hame Central Hospital
	Department of Rheumatology
	Keskussairaalankatu 7
	LAHTI, 15850
	Finland
Keszthelyi, Peter	Bekes Megyei Pandy Kalman Korhaz
	Reumatologiai Osztaly
	Semmelweis utca 1.
	GYULA, 5700
	Hungary
King, Charles	North Mississippi Medical Clinics, Inc. Clinical Research
	845 South Madison Street
	TUPELO, MS 38801
	United States
Kohen, Michael	Millennium Research
	Suite B2
	1545 Hand Avenue
	ORMOND BEACH, FL 32174
	United States
Kolasa, Renata	Medica Pro Familia SA Oddzial w Krakowie
	Ul Pradnicka 12/502
	KRACOW, 30-002
	Poland



Investigator Name	Site Name/Post Office Address
Kolba, Karen	Pacific Arthritis Center Medical Group Suite A 607 East Plaza Drive SANTA MARIA, CA 93454 United States
Kremer, Joel	The Center for Rheumatology 4 Tower Place 8th Floor ALBANY, NY 12203 United States
Kull, Mart	Medita Clinic Teguri 37b TARTU, 50107 Estonia
Kumar, Ramesh	Ocean Rheumatology, PA Suite 300 413 Lakehurst Road TOMS RIVER, NJ 08755 United States
Kuru, Omer	Ondokuz Mayis University Faculty of Medicine Discipline of Rheumatology Kurupelit SAMSUN, 55139 Turkey
Lassoued, Slim	Centre Hospitalier Jean Rougier Service de Rhumatologie 335 rue de President Wilson BP 50269 CAHORS CEDEX, 46005 France
Lee, Eric	Inland Rheumatology Clinical Trials Inc. 1238 East Arrow Highway UPLAND, CA 91786 United States
Lieberman, Jefrey	Jefrey D. Lieberman, MD, PC 2712 North Decatur Road DECATUR, GA 30033 United States



Investigator Name	Site Name/Post Office Address
Loiseau-Peres, Sylvie	CHR Orleans - Hopital de la Source
	Nouvel Hopital Orleans La Source
	Service I.P.R.O.S
	14 avenue de l'Hopital, Cedex 2
	ORLEANS, 45067
	France
Ludivico, Charles	East Penn Rheumatology Associates
	Suite 402
	701 Ostrum Street
	BETHLEHEM, PA 18015
	United States
Luggen, Michael	Cinncinnati Rheumatic Disease Study Group, Inc.
	311 Straight Street, 2nd Floor
	CINCINNATI, OH 45219
	United States
Lukacova, Olga	Narodny ustav reumatickych chorob Piestany
	Reumatologicka ambulancia
	Nabrezie Ivana Krasku 4
	PIESTANY, 92112
	Slovakia
Mabaquiao, Arthur	TriWest Research Associates, LLC
	Suite 201
	300 South Pierce Street
	EL CAJON, CA 92020
	United States
Macejova, Zelmira	ARTROMAC n.o.
	Neurologicka a reumatologicka ambulancia
	Poliklinika Terasa
	Toryska ul. 1
	KOSICE, 040 11
	Slovakia
Maertens, Martin	AZ Damiaan
	Gouwelozestraat 100
	OSTEND, 8400
	Belgium



Investigator Name	Site Name/Post Office Address
Mallepalli, Jyothi	Arthritis and Diabetes Clinic, Inc.
	3402 Magnolia Cove
	MONROE, LA 71203
	United States
Maw, Win Win	Broomfield Hospital
	Mid Essex Hospitals NHS Trust
	Research Office, Ground Floor C254, West Wing
	Court Road
	CHELMSFORD, ESSEX, CM1 7ET
	United Kingdom
McKay, Neil	Western General Hospital
•	1st Floor, Clock Tower Building
	Crewe Road
	EDINBURGH, EH4 2XU
	United Kingdom
Megyaszai, Marta	Revita Reumatologiai Rendelo
	Margit krt. 50-52. fsz. 9
	BUDAPEST, 1027
	Hungary
Metyas, Samy	Medvin Clinical Research
• .	Suite A
	500 W. San Bernardino Road
	COVINA, CA 91722
	United States
Miller, Marc	Rheumatology Associates
	51 Sewall Street
	PORTLAND, ME 04102
	United States
Mosesova, Nino	Family Outpatient clinic #4, LLC
	33, Stancionnaya str.
	KOROLEV, 109044
	Russian Federation
Nami, Alireza	Joint & Muscle Research Institute
•	332 Lillington Avenue
	CHARLOTTE, NC 28204
	United States



Investigator Name	Site Name/Post Office Address
Neal, Nathaniel	Valerius Medical Group and Research Center of Greater Long Beach
	Suite 104
	10861 Cherry Street
	LOS ALAMITOS, CA 90720
	United States
Neiman, Abigail	Pioneer Research Solutions, Inc
	10700 Stancliff Road
	HOUSTON, TX 77099 United States
Ong, Voon	The Royal Free London Foundation Trust
	Pond Street
	LONDON, NW3 2QG
	United Kingdom
Palmer, William	Westroads Clinical Research, Inc.
	10170 Nicholas Street
	OMAHA, NE 68114 United States
D 1 7	
Pando, Jose	Delaware Arthritis
	20268 Plantations Road
	LEWES, DE 19958 United States
Dana Chinler	
Pang, Shirley	St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Hospital
	Suite 25000
	2141 North Harbor Boulevard
	FULLERTON, CA 92835
	United States
Park, Won	Inha University Hospital
24,	Rheumatology
	27, Inhang-ro, Jung-gu
	INCHEON, 22332
	Korea, Republic Of
Pavlova, Dace	LTD M&M Centrs
	Gaujas Street 11-6
	ADAZI, LV-2164
	Latvia



Investigator Name	Site Name/Post Office Address
Pegram, Samuel	Rheumatic Disease Clinical Research Center
	4825 Almeda Road
	HOUSTON, TX 77004
	United States
Pereira, Joaquim	Centro Hospitalar de Lisbon Norte, EPE
	Servico de Reumatologia, Hospital de Santa Maria
	Avenida Professor Egas Moniz
	LISBON, 1649-035
	Portugal
Perruquet, James	Coastal Carolina Health Care, P.A.
	702 Newman Road
	NEW BERN, NC 28562
	United States
Peters, Eric	Arizona Arthritis & Rheumatology Research, PLLC
	Suite 100
	5681 West Beverly Lane
	GLENDALE, AZ 85306
	United States
Pickrell, Paul	Tekton Research, Inc.
	Suite 110
	4534 Westgate Boulevard
	AUSTIN, TX 78745
	United States
Pinto, Patricia	Centro Hospitalar De Vila Nova De Gaia Espinho, EPE
	Servico de Reumatologia
	Rua Conceicao Fernandes
	VILA NOVA DE GAIA, 4434-502
	Portugal
Pocurull, Ricardo	Arthritis & Osteoporosis Clinic of Brazos Valley
,	Suite 204
	1721 Birmingham Drive
	COLLEGE STATION, TX 77845
	United States



Investigator Name	Site Name/Post Office Address
Prothmann, Ulrich	Akademisches Lehrkrankenhaus der Universitaet des Saarlandes
	Klinik fuer Rheumatologie und Klinische Immunologie
	Knappschaftsklinikum Saar GmbH
	In der Humes 35
	PUETTLINGEN/SAAR, 66346
	Germany
Querubin, Roel	Marietta Rheumatology Associates
	Suite 100
	670 North Avenue
	MARIETTA, GA 30060
	United States
Rehman, Qaiser	Rheumatology Clinic of Houston
	Suite 240
	11307 FM 1960 West
	HOUSTON, TX 77065
	United States
Resch, Heinrich	Rheuma-Zentrum Wien-Oberlaa
	Kurbadstrasse 14
	VIENNA, 1100
	Austria
Rigby, William	Dartmouth-Hitchcock Medical Center
	Section of Rheumatology
	One Medical Center Drive
	LEBANON, NH 03756
	United States
Rischmueller, Maureen	The Queen Elizabeth Hospital
	28 Woodville Road
	WOODVILLE SOUTH, SA 5011
	Australia
Rizk, Milad	Vastmanlands Sjukhus
	Reumatologkliniken
	VASTERAS, 721 89
	Sweden



Investigator Name	Site Name/Post Office Address
Roman Ivorra, Jose	Hospital Universitario y Politecnico La Fe
	Servicio Reumatologia
	Torre B, 6 ^a planta.
	Avda. Fernando Abril Martorell 106.
	VALENCIA, 46026
	Spain
Rosner, Itzhak	Bnai Zion Medical Center
	Department of Rheumatology
	47 Eliyahu Golomb Street
	HAIFA, 3339419
	Israel
Rubbert-Roth, Andrea	Uniklinik Koln, Klinik I fur Innere Medizin
	Immunologische Ambulanz
	Kerpener Str.62
	COLOGNE, 50937
	Germany
Salomonsson, Per	Orebro Universitetssjukhuset
	Avd. For kliniska provningar/Clinical Trials Unit
	S-huset
	OREBRO, 701 85
	Sweden
Schulze-Koops, Hendrik	Klinikum der Universitaet Munich
	Rheumaeinheit
	Medizinische Klinik und Poliklink IV
	Pettenkoferstr. 8a
	MUNICH, 80336
	Germany
Scoville, Craig	Institute of Arthritis Research
, ,	2220 East 25th Street
	IDAHO FALLS, ID 83404
	United States
Sfikakis, Petros	General Hospital of Athens "Laiko"
	A Propaeudeutic Medicine Dept
	17 Agiou Thoma Street
	ATHENS, 11527
	Greece



Investigator Name	Site Name/Post Office Address
Shanahan, Joseph	Shanahan Rheumatology and Immunotherapy, PLLC Suite 301 10208 Cerny Street RALEIGH, NC 27617 United States
Shergy, William	Rheumatology Associates of North Alabama PC Suite 500 720 Gallatin Street HUNTSVILLE, AL 35801 United States
Singhal, Atul	SW Rheumatology Res. LLC Suite 200 1600 Republic Parkway MESQUITE, TX 75150 United States
Sirova, Klara	Revmatologie MUDr. Klara Sirova, s r.o. Chelcickeho 616/12 OSTRAVA - MORAVSKA OSTRAVA, 702 00 Czech Republic
Snow, David	Cape Fear Arthritis Care Suite 1B 1003 Olde Waterford Way LELAND, NC 28451 United States
Sternad, Patrizia	MVZ Planegg Rheumatologie Dr. Martin Welcker GmbH Bahnhofstr. 32 PLANEGG, 82152 Germany
Su, Tien-I	Medvin Clinical Research 12456 Washington Blvd. WHITTIER, CA 90602 United States



Investigator Name	Site Name/Post Office Address
Surbeck, William	Healthcare Research Consultants, LLC Suite A
	4619 South Harvard Ave
	TULSA, OK 74135
	United States
Swarup, Areena	Arizona Arthritis and Rheumatology Research, PLLC
	Suite 202
	1500 S. Dobson Road
	MESA, AZ 85202
	United States
Swierkot, Jerzy	WroMedica Irena Bielicka, Janusz Szczepanik s.c.
	ul. Adama Mickiewicza 91
	WROCLAW, 51-685
	Poland
Sylwestrzak, Anna	Centrum Medyczne Pratia Gdynia
	UI. Bernarda Chrazanowskiego 3/5
	GDYNIA, 81-338
	Poland
Tahir, Hasan	Whipps Cross University Hospital
	Barts Health NHS Trust
	Whipps Cross Road, Leytonstone
	LONDON, E11 1NR
	United Kingdom
Teleman, Annika	Capio Movement Halmstad
	Rheumatology
	Bergsgatan 26
	HALMSTAD, 30233
	Sweden
Thomson, Glen	Center for Inflammatory and Arthritis Disease Studies
	Research Co. Ltd.
	1835 Corydon Avenue
	WINNIPEG, MB R3N 0K6
	Canada
Torres, Arnaldo	Advent Clinical Research Centers, Inc.
•	4820 Park Blvd.
	PINELLAS PARK, FL 33781
	United States



Investigator Name	Site Name/Post Office Address	
Trapp, Robert	Springfield Clinic	
	Dept Clinical Research	
	Suite 100	
	1130 South 6th Street	
	SPRINGFIELD, IL 62703	
	United States	
Van den Bosch, Filip	University Hospital Ghent, UZ Ghent	
	Poli Reumatologie	
	Entrance 74 Building P6 second floor	
	De Pintelaan, 185	
	GENT, 9000	
	Belgium	
Van Mullem, Xavier	Rhumaconsult SPRL	
	Boulevard Audent 33	
	CHARLEROI, 6000	
	Belgium	
Vanhoof, Johan	ReumaClinic Genk	
	Jaarbeurslaan 21b22	
	GENK, 3600	
	Belgium	
Veldi, Tiina	East Tallinn Central Hospital	
	Rheumatology department	
	Parnu road 104	
	TALLINN, 11312	
	Estonia	
Walker, Nancy	Clinical Research Center of Reading	
	2760 Century Boulevard	
	WYOMISSING, PA 19610	
	United States	
Wells, Alvin	Rheumatology and Immunotherapy Ctr., LLC	
	4225 W. Oakwood Park Court	
	FRANKLIN, WI 53132	
	United States	



Investigator Name	Site Name/Post Office Address
Wolfe, Sanford	STAT Research, Inc.
	One Elizabeth Place
	Suite 230
	West Medical Plaza
	DAYTON, OH 45417
	United States
Wong, Ernest	Queen Alexandra Hospital
	Southwick Hill Road
	Portsmouth
	COSHAM, P06 3LY
	United Kingdom
Zahabi-Unwala, Fehmida	Trinity Universal Research Associates, INC
	Suite 412
	6300 Stonewood Drive
	PLANO, TX 75024
	United States
Zamani, Omid	Rheuma Zentrum Favoriten GmbH
	Quellenstrasse 181
	VIENNA, 1100
	Austria
Zisman, Devy	The Lady Davis Carmel Medical Center
, ,	Rheumatology Unit
	7 Michal St.
	HAIFA, 3436212
	Israel